Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Lapatinib,LPT1001,2021,USA,MDV,350,62,98,2,27.5,15,85,5,10,45,30,15,55,25,15,5,20,40,30,12,3,2,5,4,20,60,50,AC,Taxol,CMF,Taxol,30,25,20,40,70,55,10,40,50,60,2
Lapatinib,LPT1002,2022,Canada,Claim Database,420,68,97,3,28.1,18,82,7,12,42,32,14,52,28,14,6,22,38,32,14,4,3,6,5,22,62,52,EC,Docetaxel,AC-T,FEC,32,23,18,42,72,57,12,42,46,62,3
Lapatinib,LPT1003,2023,UK,MDV,280,65,99,1,26.8,13,88,6,9,46,31,14,56,24,16,4,19,41,29,11,2,1,4,3,19,59,49,FEC-T,AC,Docetaxel,CMF,29,26,21,39,69,54,9,39,52,59,2.5
